



# New generation of nanocarrier-loaded hydrogels: from conception to in vivo applications

Guillaume Bastiat

► **To cite this version:**

Guillaume Bastiat. New generation of nanocarrier-loaded hydrogels: from conception to in vivo applications. Séminaire de la faculté de pharmacie de Québec, Jul 2017, Montreal, Canada. hal-02616004

**HAL Id: hal-02616004**

**<https://hal.univ-angers.fr/hal-02616004>**

Submitted on 24 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## « New generation of nanocarrier-loaded hydrogels: from conception to *in vivo* applications »

**Guillaume Bastiat, Ph.D.**

Professeur adjoint, UFR Santé  
Université d'Angers  
France

À l'invitation de la professeure Gaëlle Roullin

Lundi, 10 juillet 2017  
Pavillon Jean-Coutu  
11h30 – Salle S1-125

The combination of pharmaceutical technologies can be a wise choice for developing innovative therapeutic strategies. The association of nanocarriers and gels provides new therapeutic possibilities due to the combined properties of the two technologies. Gels support the nanocarriers, localize their administration to the target tissue, and sustain their release. In addition to the properties afforded by the gel, nanocarriers can provide additional drug sustained release or different pharmacokinetic and biodistribution profiles than those from nanocarriers administered by the conventional route to improve the drug therapeutic index. An innovative free-polymer hydrogel platform was obtained by the association of lipid nanocapsules (LNCs). The hydrogel network was allowed by H-bond interactions between cross-linking agents exposed at the oil/water interfaces of LNCs. The viscoelastic properties of the hydrogels were correlated to the concentrations of both LNCs and cross-linking agent, and these mechanical properties forced the profiles of the sustained release of LNCs. Once all the LNCs are released, the main advantage of this platform compared to the conventional nanocarrier-loaded hydrogels is the absence of implant (polymer network) located at the administration site, which can lead to additional toxicities. These hydrogels are injectable using syringes and showed a good biocompatibility after an *in vivo* subcutaneous injection, with a local inflammatory response similar to that of induced by an approved excipient. Two preclinical applications of the hydrogels have been successfully explored: one to target metastasis from lung carcinoma and the other to delay the recurrences of glioblastoma after primary tumor resection.